As of Wednesday close, AbCellera Biologics Inc.’s (NASDAQ:ABCL) stock traded at $5.08. The average number of shares traded per day over the past five days has been 1,796,060 shares. 2 times new highs have been achieved over the past 5 days, with a -$0.17 fall in that time frame. In the last twenty days, the average volume was 1,536,720, while in the previous 50 days, it was 1,996,462.
Since last month, ABCL stock retreated -8.96%. Shares of the company fell to $5.06 on 09/20/23, the lowest level in the past month. A 52-week high of $14.97 was reached on 02/03/23 after having rallying from a 52-week low of $5.06. Since the beginning of this year, ABCL’s stock price has dropped by -49.85% or -$5.05, and marked a new high 7 times. However, the stock has declined by -66.07% since its 52-week high.
ABCL stock investors should be aware that AbCellera Biologics Inc. (ABCL) stock had its last reported insider trading activity 118 days ago on May 26. Thermopylae Holdings Ltd., the 10% Owner of the company, purchased of 153,000 shares for $6.52 on May 26. It resulted in a $997,728 investment by the insider. Booth Andrew added 14,500 shares at an average price of $6.85 on May 26. The insider now owns 153,000 shares following the transaction. On Dec 16, 10% Owner Thermopylae Holdings Ltd. bought 85,102 shares at $10.10 apiece. The transaction was valued at $859,249.
Valuation Metrics
The stock’s beta is 0.02. Besides these, the trailing price-to-sales (P/S) ratio of 9.80, the price-to-book (PB) ratio of 1.23.
Financial Health
In the three months ended June 29, AbCellera Biologics Inc.’s quick ratio stood at 7.80, while its current ratio was 7.80, showing that the company is able to pay off its debt. In the year ended June 29, EBITDA margin amounted to 65.11%, whereas operating margins totaled -80.10%. Based on annual data, ABCL earned $268.91 million in gross profit and brought in $485.42 million in revenue.
A company’s management is another factor that investors consider when determining the profitability of an investment. In the past year, return on investment (ROI) was 11.00%. Return on equity (ROE) for the past 12 months was -6.00%.
According to the earnings report, the company had a lower net income in the recent quarter than it did in the previous quarter. ABCL’s revenue fell -356.46% to $12.19 million during the quarter, while net income inched up to $10.06 million. While analysts expected AbCellera Biologics Inc. to report -$0.13 quarterly earnings, the actual figure was -$0.11 per share, beating the consensus estimate by 15.40%. During the quarter, the company generated -$44.13 million in EBITDA. The liabilities of AbCellera Biologics Inc. were 342.34 million at the end of its most recent quarter ended June 29, and its total debt was $84.03 million. The value of shareholders’ equity is $289.36 million.
Technical Picture
This quick technical analysis looks at AbCellera Biologics Inc.’s (ABCL) price momentum. With a historical volatility rate of 37.64%, the RSI 9-day stood at 33.48% on 20 September.
With respect to its five-day moving average, the current AbCellera Biologics Inc. price is down by -3.24% percent or -$0.17. At present, ABCL shares trade -7.64% below its 20-day simple moving average and -23.49% percent below its 100-day simple moving average. However, the stock is currently trading approximately -24.74% below its SMA50 and -61.46% below its SMA200.
Stochastic coefficient K was 2.22% and Stochastic coefficient D was 8.89%, while ATR was 0.22. Given the Stochastic reading of 2.70% for the 14-day period, the RSI (14) reading has been calculated as 34.46%. As of today, the MACD Oscillator reading stands at -0.12, while the 14-day reading stands at -0.23.
Analyst Ratings
Cowen launched its rating on AbCellera Biologics Inc. (NASDAQ: ABCL) to an Outperform in a note to investors on February 28, 2023. AbCellera Biologics Inc. (ABCL) has been rated Buy by analysts. According to 0 brokerage firms, ABCL is a sell, and 0 firms recommend it is a Hold. There are 0 analysts who say the stock is underweight. A total of 0 analysts rate AbCellera Biologics Inc. stock as buy, with 8 recommending it as overweight.
With a median target price of $28.00, the current consensus forecast for the stock is $12.00 – $34.00. Based on these forecasts, analysts predict AbCellera Biologics Inc. (ABCL) will achieve an average price target of $24.43.
